Lab Work Before GLP-1: What to Know

See if you qualify in 5 minutes →
5-minute questionnaire · reviewed by a licensed clinician · 30-day money-back guarantee — a full refund on 3-month and 6-month plans · cancel anytime

At a glance

Lab	What it checks	Why it matters for GLP-1
A1c (HbA1c)	Average blood sugar over ~3 months	Reveals undiagnosed diabetes (≥6.5%) or prediabetes (5.7–6.4%); changes the clinical picture significantly
Comprehensive metabolic panel	Kidney & liver function, electrolytes	Reduced kidney function affects how the medication is monitored over time
Lipid panel	Cholesterol & triglycerides	Often elevated with obesity; useful baseline for tracking metabolic progress
TSH (thyroid)	Thyroid function	Rules out hypothyroidism as an independent contributing factor to weight changes

Eligibility, prices, and state requirements are confirmed by a licensed clinician — information is current as of June 2026.

Are labs required before a GLP-1?

Legally, no. The FDA prescribing label for semaglutide (Wegovy) does not mandate pre-treatment bloodwork, so a prescription without labs is not illegal. Clinically, baseline labs are recommended best practice — the NIDDK's guidance on prescription weight-loss medications describes the kind of clinical evaluation that should accompany these therapies. Labs establish a starting point and catch issues — an unsuspected diabetic A1c, low kidney function, an untreated thyroid condition — that can change the dose or the decision entirely.

What the bloodwork checks

A typical baseline panel includes:

• A1c (HbA1c) — average blood sugar over approximately three months. An A1c of 5.7–6.4% indicates prediabetes; ≥6.5% indicates diabetes. Semaglutide-class drugs were originally developed as diabetes medications, so knowing whether you already have diabetes — or are close to the threshold — changes the clinical picture significantly.
• Comprehensive metabolic panel (CMP) — kidney function (creatinine, BUN), liver enzymes (ALT, AST), and electrolytes. Reduced kidney function affects how the medication is monitored over time and may affect suitability.
• Lipid panel — cholesterol and triglycerides. These are commonly elevated in people with obesity and serve as a useful metabolic baseline for tracking progress.
• TSH (thyroid-stimulating hormone) — rules out hypothyroidism and other thyroid conditions that can contribute independently to weight gain and difficulty losing weight.

Ongoing monitoring labs — periodic kidney and liver check-ins during treatment — are good practice at more rigorous providers. Large semaglutide trials, including the STEP-1 study (Wilding et al., NEJM 2021), tracked A1c, lipids, and kidney function throughout as standard metabolic parameters. That research was conducted on the branded molecule semaglutide 2.4 mg — not on any compounded product — but it reflects the same clinical benchmarks providers use when evaluating patients today.

What "no labs required" really means

Many telehealth providers don't require labs, relying on your health-history intake form instead. That's legal, but it is a quality trade-off — not a feature to advertise. The best providers offer or encourage baseline labs where clinically indicated, because screening protects you. Think of labs as part of real clinical care, not an obstacle to starting.

The FDA's BeSafeRx guidance on obtaining medications online emphasizes that a legitimate provider should conduct a proper medical evaluation before prescribing. A thorough evaluation — especially for YMYL medications like GLP-1s — typically includes reviewing your health history and, where clinically indicated, recent lab work. For more on what separates a quality telehealth program from a low-bar one, see our guide on how to choose a GLP-1 telehealth provider.

Compounded GLP-1 medications: same lab considerations

If you're evaluating a program that uses compounded semaglutide or tirzepatide — rather than brand-name Wegovy, Ozempic, Zepbound, or Mounjaro — the relevant lab considerations are the same. Compounded GLP-1 medications are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. The FDA's overview of human drug compounding explains the 503A regulatory framework these pharmacies operate under. The clinical safety questions that baseline labs help answer — blood sugar, kidney function, thyroid status — apply regardless of whether the medication is brand-name or compounded, and are not changed by where the medication originates.

For context on the FDA's guidance on unapproved GLP-1 drugs used for weight loss, the agency's concern centers on oversight quality — which is exactly the argument for proper lab-based clinical evaluation before prescribing.

Related getting-started guides

• How Online GLP-1 Programs Work — the full process from intake to shipment
• Do You Qualify for a GLP-1? — BMI thresholds and clinical criteria
• How Long It Takes to Get Semaglutide Online — timeline from intake to first dose
• GLP-1 Cost in 2026 — what programs include and how prices compare

How Nouri works

Nouri is built to be a legitimate, thorough option. You complete a 5-minute online questionnaire; a U.S.-licensed clinician reviews your file — a real evaluation, with a video visit where your state requires one — and, if appropriate, your therapy ships discreetly from a named, state-licensed 503A pharmacy (Jungle Jim's Pharmacy, Fairfield, OH). Nouri is LegitScript-certified, available in all 50 states, and includes a nutrition plan and a movement plan at one all-inclusive price. Plans are compounded semaglutide from $120/month on the 6-month plan and compounded tirzepatide from $175/month on the 6-month plan. Your start is backed by the Nouri Promise: a 30-day money-back guarantee — a full refund on the 3-month and 6-month plans.

Compounded GLP-1 medications are not FDA-approved and are not the same as the brand-name drugs.

Start your 5-minute assessment →
5-minute questionnaire · reviewed by a licensed clinician · 30-day money-back guarantee — a full refund on 3-month and 6-month plans · cancel anytime

Frequently asked questions

What blood tests do you need before semaglutide?

Commonly an A1c (blood sugar), a comprehensive metabolic panel (kidney and liver function), a lipid panel, and often TSH (thyroid). These establish a baseline and catch issues that could change the plan. No law requires them, but they are recommended best practice.

Can you get a GLP-1 without bloodwork?

Yes — many telehealth providers don't require labs and prescribe based on your health history. It's legal, but baseline bloodwork is the clinical ideal, and a provider that does no screening at all is a quality concern.

Do you need labs before Ozempic?

There's no legal requirement, but a thorough clinician typically reviews or recommends baseline labs (A1c, metabolic panel, lipids, thyroid) before starting any GLP-1, including Ozempic. It's a recommended safety step, not a barrier.

How recent do labs need to be?

Providers usually want recent labs — often within the past 6–12 months — so they reflect your current health. Your clinician will tell you whether existing labs are recent enough or new ones are needed.

Do you need blood work before Wegovy?

There's no legal requirement, but a thorough clinician typically reviews or recommends baseline blood work (A1c, a metabolic panel, lipids, and thyroid) before starting Wegovy or any GLP-1. It's a recommended safety step, not red tape.

What does the bloodwork check for?

Mainly blood sugar (A1c), kidney and liver function (metabolic panel), cholesterol (lipids), and thyroid (TSH) — to establish a baseline and rule out issues that affect GLP-1 dosing or safety.

Sources & references

1. NIDDK: Prescription Medications to Treat Overweight & Obesity — National Institute of Diabetes and Digestive and Kidney Diseases (Tier 1 — NIH/.gov).
2. Wegovy (semaglutide injection 2.4 mg) FDA Prescribing Information — FDA, 2025 label (Tier 1 — FDA).
3. FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — FDA postmarket safety guidance (Tier 1 — FDA).
4. FDA BeSafeRx: Your Source for Online Pharmacy Information — FDA guidance on legitimate online prescribing (Tier 1 — FDA).
5. FDA: Human Drug Compounding — FDA overview of 503A and 503B compounding pharmacy regulations (Tier 1 — FDA).
6. Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384:989–1002. DOI: 10.1056/NEJMoa2032183 — STEP-1 trial; research on the branded molecule semaglutide 2.4 mg, not on any compounded product (Tier 1 — NEJM).

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as guidance changes. Author: Nouri Editorial Team.

This article is general education, not medical advice — eligibility and prescribing decisions are made by a licensed clinician based on your individual evaluation. Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly; Nouri is not affiliated with, endorsed by, or sponsored by these companies. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. Telehealth prescribing requirements vary by state and may change. Information is current as of June 2026.